Please select the eligibility criteria that correspond to the clinical trial below.
Title: Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)
Brief Summary: The purpose of this study is to test whether the drug, atorvastatin, will be able to reduce the rate of return of the abnormal beats after using cardioversion. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol but is not approved for preventing abnormal heartbeats. In addition to lowering cholesterol, the drug reduces inflammation. Inflammation seems to help cause atrial fibrillation, a certain type of abnormal heartbeat. In animals, atorvastatin reduces the risk of this type of abnormal beats, and preliminary data in humans supports an effect of atorvastatin and other similar drugs that have the same action on reducing the risk of this type of abnormal beats. We, the researchers at Emory University, would like to learn if this drug could prevent the return of these abnormal heartbeats.


Options:
A: Inclusion Criteria:

* diagnosed for PCOS (Rotterdam criteria)
* aged 30-50 years
* safe non-hormonal contraception

Exclusion Criteria:

* use of cholesterol lowering agents
* use of antidepressants
* use of cortisone medication (p.o.)
* use of hormonal contraception
* nursing
* pregnancy
* DM-T2
* liver disease
* menopause
* kidney or liver failure
B: Inclusion Criteria: Women with PCOS

* 8 or fewer menstrual periods per year
* elevated serum total testosterone
* elevated LDL cholesterol

Exclusion Criteria:

* current pregnancy or breastfeeding
* current use of oral contraceptives, progestins
* insulin sensitizing medications
* thyroid disease, hyperprolactinemia, active liver disease, type 1 or type 2 diabetes
C: Inclusion Criteria:

* \> or = 18 years of age
* Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)
* Able to swallow pill form of drug

Exclusion Criteria:

* \< 18 years of age
* enrollment in another ongoing trial
* paroxysmal atrial fibrillation
* hemodynamic instability
* atrial fibrillation ablation within 6 months of enrollment
* a contraindication for anticoagulation
* severe valvular heart disease
* presence of single lead implantable cardioverter defibrillator
* unstable angina
* New York Heart Association (NYHA) Class IV heart failure
* hyperthyroidism
* uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications
* an illness that would limit life expectancy to less than 1 year
* use of statins within the previous 30 days
* significant coronary artery disease or lipid abnormalities necessitating statin therapy
* implanted devices for active management of arrhythmias by pacing or defibrillation
* lack of access to a telephone
* illicit drug use
* alcohol abuse
* hypersensitivity to atorvastatin by history
* pregnancy
* sexually active female subjects not on contraception or surgically sterilized
* nursing mothers
* chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal \[ULN\] of laboratory reference range)
* severe renal disease (creatinine \> 200 mmol/L)
* inflammatory muscle disease or creatine kinase (CK) \> 3 times ULN
* concurrent treatment with cyclosporine, fibrates, or high-dose niacin
D: Inclusion Criteria:

* Meets American College of Rheumatology (ACR) revised diagnostic guidelines for SLE
* Weight of 25 kg (55 lbs) or more
* Outpatient
* Ability to complete self-report questionnaires in either English or Spanish
* Willingness to comply with recommended diet
* Acceptable methods of contraception

Exclusion Criteria:

* Drug-induced lupus
* Liver disease (ALT or aspartate aminotransferase greater than 2 X normal value)
* Myositis (CK greater than 3 X normal value)
* Inability to obtain adequate-quality IMT images
* Current use of oral or parenteral tacrolimus or cyclosporine
* Dialysis or serum creatinine reater than 2.5 mg/dL
* Active nephrotic syndrome (urinary protein greater than 3 g/24 h and serum albumin less than 2.3 g/dl)
* Total cholesterol greater than 350 mg/dL
* Xanthoma
* Familial hypercholesterolemia
* Pregnant or breastfeeding
* Use of estrogen-containing contraceptives (e.g., Lo-Ovral)
* Unable to adhere to study regimen
* Life-threatening non-SLE illness that would interfere with ability to complete the study
* Current drug or alcohol abuse
* Anticipated poor compliance
* Participation in another drug intervention study within 30 days of study enrollment

Answer: C